Koya Medical's Andy Doraiswamy Honored as Exceptional Entrepreneur by Goldman Sachs

Koya Medical's Remarkable Recognition at Goldman Sachs' Summit

On October 15, 2025, Koya Medical's CEO, Andy Doraiswamy, PhD, was celebrated as one of the Most Exceptional Entrepreneurs at the prestigious Builders and Innovators Summit organized by Goldman Sachs in Healdsburg, California. This acknowledgment cements Koya's position as a pioneering entity in the vascular health sector, showcasing not only entrepreneurial brilliance but also significant contributions to medical innovation.

The Builders and Innovators Summit, now in its 14th year, gathers some of the brightest minds in business. It serves as a platform for networking, sharing insights, and recognizing individuals who drive substantial changes in their respective fields. Goldman Sachs, a highly regarded global financial institution, selected Doraiswamy from various industries, illustrating the wide-reaching impact of his work at Koya.

Koya Medical, founded in 2018 and headquartered in Dallas, is primarily focused on redefining vascular health. Under Doraiswamy's leadership, the company has developed comprehensive, patient-centered solutions aimed at bridging existing treatment gaps in vascular care. His previous achievements in ophthalmology, particularly in creating sight-restoring intraocular implants, have already benefited over ten million people worldwide. These innovations, which were acquired by Santen Pharmaceutical Co., Ltd., and are distributed by Bausch + Lomb, underscore Doraiswamy's commitment to health innovations.

During his acceptance speech at the summit, Doraiswamy expressed gratitude for the recognition and emphasized the collaborative spirit of the Koya Medical team. “This recognition is a reflection of the Koya Medical team's dedication to pioneering a comprehensive vascular care solution across the home, office, and surgical continuum,” he stated. His words encapsulated the essence of what drives the company: a mission to make health accessible and equitable.

David Solomon, Chairman and CEO of Goldman Sachs, commended Doraiswamy, stating, “We are pleased to recognize Andy Doraiswamy as one of the most exceptional entrepreneurs of 2025. The Koya Medical team have not only built a successful enterprise, they are redefining industry paradigms.” Solomon’s words highlight the disruptive potential that Koya Medical embodies in a rapidly evolving healthcare landscape.

One of the pressing issues that Koya Medical addresses is the critical state of vascular health in America. Over 35 million Americans are living with venous and lymphatic diseases, which are often underrecognized yet can significantly impair quality of life. Koya Medical aims to provide modern, evidence-based solutions designed to improve treatment access, improve mobility, and enhance overall health outcomes.

As the summit opened discussions on harnessing artificial intelligence and next-generation business practices, Koya Medical stood out not just for their achievements but for the potential they carry for future innovations. Their FDA-approved Dayspring treatment system exemplifies their approach to tackling real-world health issues head-on.

In closing, Koya Medical’s recognition at the Goldman Sachs Summit is a monumental event, not only for the company itself but for the broader healthcare community. It reflects a growing acknowledgment of the importance of addressing vascular health and serves as an inspiration for other entrepreneurs and business leaders aiming to make impactful contributions in their fields. As Koya pushes forward, they continue to inspire a collective movement towards innovative, accessible healthcare solutions.